News

Former Roche executive Abercrombie named to BioCryst board

Former Roche executive George Abercrombie has been elected to BioCryst Pharmaceuticals‘ (NASDAQ:BCRX) board of directors, his second appointment to the board of a North Carolina pharmaceutical company in the last month. In September, Abercrombie was named to the board of Tranzyme Pharma (NASDAQ:TZYM). Both companies are based in Durham, North Carolina. Abercrombie, who has more […]

Former Roche executive George Abercrombie has been elected to BioCryst Pharmaceuticals‘ (NASDAQ:BCRX) board of directors, his second appointment to the board of a North Carolina pharmaceutical company in the last month.

In September, Abercrombie was named to the board of Tranzyme Pharma (NASDAQ:TZYM). Both companies are based in Durham, North Carolina.

Abercrombie, who has more than 30 years of experience in the pharmaceutical industry, takes the place of Stephen Biggar, who stepped down from BioCryst’s board effective Monday. Abercrombie was president and CEO of Roche’s North American operations from 2001 to 2009. He also worked at Glaxo Wellcome where his executive roles included serving as senior vice president of Glaxo’s U.S. commercial operations. Before Glaxo, Abercrombie spent more than 10 years at Merck (NYSE:MRK).

BioCryst is in phase 3 clinical trials for flu treatment peramivir. It is also in mid-stage clinical trials for BCX4208, a compound being studied as a new gout treatment.

“As the company advances its late-stage assets, the BioCryst team and its Board of Directors should benefit from George’s expertise and guidance, and we look forward to his contributions,” BioCryst chairman Zola Horovitz said in a prepared statement.

Abercrombie was recently on the board of Durham-based Inspire Pharmaceuticals, which was acquired by Merck earlier this year. Abercrombie is also chairman of the board of Fort Lauderdale, Florida skin treatments company Brickell Biotech.

Abercrombie has a bachelor’s degree in pharmacy from the University of North Carolina at Chapel Hill and an MBA from Harvard University.